# Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

> **NCT06792214** · PHASE4 · RECRUITING · sponsor: **Mount Sinai Hospital, Canada** · enrollment: 118 (estimated)

## Conditions studied

- SARS CoV-2 Post-Acute Sequelae

## Interventions

- **DRUG:** Nirmatrelvir/ritonavir
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT06792214
- **Lead sponsor:** Mount Sinai Hospital, Canada
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2026-01
- **Final completion:** 2027-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2025-01-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06792214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06792214, "Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06792214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*